Drug intelligence / Profile preview

inactivated hepatitis A vaccine (TZ84 strain)

Development stage
Unknown
Lead developer
Sinovac Biotech
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

The Inactivated HAV Vaccine, TZ84 Strain is a biological vaccine developed by the Institute of Medical Biology, Chinese Academy of Medical Sciences (IMBCAMS) for the prevention of hepatitis A infection. It utilizes the TZ84 strain of the hepatitis A virus (HAV), which has been adapted to replicate in vitro and is subsequently inactivated. The vaccine is administered intramuscularly, typically in a two-dose schedule with a booster at six months. Clinical studies have demonstrated that the TZ84-strain vaccine provides superior immunogenicity, with protection potentially lasting up to 30 years, and exhibits fewer adverse reactions compared to other inactivated hepatitis A vaccines. It has also shown efficacy in controlling community-wide outbreaks.

Other names
inactivated hepatitis A vaccine TZ84Inactivated HAV Vaccine, TZ84 Strain
02

Targets

BCR (Immunoglobulin G B Cell Receptor)Hepatitis A virus capsid proteinPRR (Pattern recognition receptors)

Beyond the preview

Go deeper on inactivated hepatitis A vaccine (TZ84 strain).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on inactivated hepatitis A vaccine (TZ84 strain).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call